Lawmakers demand details on 1,400% price hike for cancer drug

While NextSource's lomustine is no longer under patent protection, the company is currently the only manufacturer of the drug.

By Randi Hernandez • April 4, 2018

NICE's first impression of Dupixent: It's not cost-effective

Sanofi and Regeneron's potential blockbuster doesn't meet the requirements to be "an acceptable use of NHS resources," the U.K. body found.

By Jacob Bell • April 4, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Amgen's money-back offer on Repatha isn't all that meaningful, researchers find

A new study suggests Amgen's outcomes-based payment scheme would only marginally improve the cost-effectiveness of the PCSK9 drug.

By Ned Pagliarulo • April 4, 2018

Pharma turns to new pain options amid opioid crisis

In its latest spotlight, BioPharma Dive explores the drug industry's efforts to develop novel approaches to treat pain and deter abuse.

By Lisa LaMotta • April 4, 2018

PhRMA argues early notice of price hikes won't benefit patients

Letting insurers, distributors and PBMs know when a drug's price is about to increase, as some state laws aim to do, could encourage drug stockpiling and shortages, the trade group said.

By Jacob Bell • April 2, 2018

Walmart reportedly in early talks to acquire Humana

The companies already partner on Medicare Part D drug plans. But a deal could boost Humana's group market offerings to compete with other insurers, suggests one analyst.

By David Lim • April 2, 2018

Teva's 'skinny label' generic didn't cause infringement of GSK's patent, judge finds

The decision means Teva doesn't have to fork over $235 million in lost profits and royalties to its pharma rival, as a jury previously ruled.

By Jacob Bell • March 29, 2018

Teva launches generic version of Shire's top-selling internal medicine

Lialda sales are already waning due to competition from other copycats, and will likely fall further as this latest rollout takes its toll.

By Jacob Bell • March 28, 2018

PhRMA goes after drug 'middlemen' in new ad attack

The trade group accused insurers and PBMs of preventing patients from reaching their deductibles by changing how copay coupons are processed. 

By Ned Pagliarulo • March 28, 2018

Sanofi aims to lower copay costs with higher-capacity Toujeo pen

The French drugmaker said the new delivery device for the long-acting insulin could potentially help reduce refills and patient copays.

By Randi Hernandez • March 28, 2018

Aetna to offer point of sale pharmacy rebates to 3M customers

The insurer has opposed an idea from CMS to mandate Part D sponsors pass on a percentage of rebates to customers at the point of sale.

By David Lim • March 27, 2018

Opioid antagonists vs. agonists: A battle to fight addiction

With no end in sight to the opioid crisis, treatments to help people suffering from addiction are taking center stage but still face stigma.

By Lisa LaMotta • March 26, 2018

Abuse deterrents still finding their niche in the pain space

Hard-to-abuse opioids haven't been on the market for very long, and whether they have staying power amid a public health crisis remains an open question.

By Jacob Bell • March 26, 2018

EMA clears biosimilars for Herceptin, Remicade

Friday's recommendations also included approval of GSK's Juluca, moving the once-daily, single-tablet maintenance therapy for HIV nearer to the market.

By Suzanne Elvidge • March 26, 2018

What's more prescribed than opioids? Weirdly, a thyroid drug

A new GoodRx report finds the most popular drug in 26 states is levothyroxine, which breached 100 million prescriptions annually from 2012 to 2016. 

By Jacob Bell • March 23, 2018

Amgen taps Omnicom's Hearts & Science for media job

The California biotech has placed its media spend in the hands of an Omnicom agency after 14 years with another group. 

By Suzanne Elvidge • March 23, 2018

Roche's Hemlibra to be biggest blockbuster of next 5 years, report says

A dozen drugs approved in 2017 should reach blockbuster status over the five-year period, with many exceeding $2 billion in annual sales, according to a report from Clarivate Analytics.

By Lisa LaMotta • March 22, 2018

Sun Pharma breaks into biologics with Ilumya

Though it's an important milestone, some analysts noted the generics giant and its new psoriasis drug will face an uphill battle in the fight for market share.

By Jacob Bell • March 22, 2018

FDA to study how drug promotion affects doctors' decisions

Drugmakers spend billions of dollars trying to get their products in front of prescribers, and the FDA wants to know how influential that practice has become.

By Jacob Bell • March 21, 2018

Broad pharmacy availability set to boost GSK's Shingrix

CVS and Walgreens now stock GSK's shingles vaccine at pharmacies nationwide, which will help the pharma steal market share from Merck.

By Randi Hernandez • March 21, 2018

Mundipharma inks third biosimilar deal with Celltrion

The European conglomerate will commercialize the South Korean company's copycat version of Herceptin.

By Lisa LaMotta • March 20, 2018

Docs more likely to prescribe opioids after pharma pay, study finds

Opioid manufacturers paid physicians more than $43 million over a two-year period, according to CareDash.

By Meg Bryant • March 16, 2018

Federal panel calls for 'urgent action' on cancer drug prices

Rising drug costs have sparked concerns over patient access while also luring greater investment by drugmakers. 

By Ned Pagliarulo • March 14, 2018

Copay exceeds drug cost in 23% of claims: JAMA research

Due to limits on what a pharmacist can say, patients are often not aware if their copay is more than what the insurer paid the pharmacy for a drug.

By Randi Hernandez • March 14, 2018

Administrative, drug costs drive US health spending far above other nations

A study published in JAMA found the U.S. pays roughly twice as much for healthcare than other high-income countries, despite similar utilization rates.

By Les Masterson • March 13, 2018